CVS Caremark will restore coverage of Eli Lilly's blockbuster weight-loss drug Zepbound by October 1, backing down after stripping the medication from its formulary last year and forcing millions of patients to scramble for alternatives. The reversal follows a class-action lawsuit and widespread complaints from patients who found themselves paying hundreds of dollars a month out of pocket, or switching to a rival drug they didn't choose.
Eli Lilly announced Thursday that Zepbound will return to CVS Caremark's standard formulary and that some patients with private insurance could pay as little as a $25 copay, NBC News reported. A CVS Caremark spokesperson said the change applies to its standard formulary and affects roughly 25 million to 30 million people.
That is a staggering number of insured Americans whose drug access hinges on behind-the-scenes negotiations between a pharmacy benefit manager and a pharmaceutical giant, negotiations that patients have no seat at and little visibility into.
When CVS Caremark dropped Zepbound from its formulary last year, the practical effect was immediate and painful. Patients who had been prescribed the drug, which carries a list price of $1,086 per month, were pushed off their medication or forced onto Novo Nordisk's Wegovy, a competitor they hadn't necessarily chosen with their doctor.
Even with Eli Lilly's cash discount programs, patients still faced out-of-pocket costs of hundreds of dollars a month. For working families already squeezed by inflation and rising healthcare premiums, that is not a minor inconvenience. It is a real financial hit driven by a corporate formulary decision made far from any exam room.
The backlash was fierce enough to produce a class-action lawsuit, filed in September and still active. The details of the litigation, the specific claims, the named parties, the court, remain unclear. But the mere existence of such a suit underscores how deeply the removal cut.
The broader problem of opaque drug pricing continues to affect patients across the country. One Kansas husband discovered his wife's $13,000 cancer drug was available for $40 through a discount pharmacy, a reminder that the gap between list prices and actual costs often defies common sense.
Pharmacy benefit managers like CVS Caremark wield enormous power over which drugs Americans can afford. They negotiate rebates with drugmakers, build formularies that determine coverage, and effectively pick winners and losers in the pharmaceutical marketplace. When CVS Caremark pulled Zepbound, it handed a competitive advantage to Novo Nordisk's Wegovy, regardless of what individual patients and their doctors preferred.
The decision to reverse course now raises its own questions. CVS Caremark has not publicly stated why it changed direction. Was it the lawsuit? The patient complaints? A better rebate deal from Eli Lilly? Some combination? NBC News did not report a stated rationale from CVS Caremark, and the company's spokesperson offered only the scope of the change, not the reason behind it.
What we do know is that the other two major pharmacy benefit managers, Express Scripts and Optum Rx, already cover Zepbound. CVS Caremark was the outlier, and now it is falling back in line.
The Zepbound restoration is not the only development on CVS Caremark's formulary. Eli Lilly's Foundayo, a weight-loss pill approved by the FDA in April, is being added to the formulary starting this week. That gives Lilly two covered weight-loss products on CVS Caremark's list, a significant commercial foothold.
Zepbound and Lilly's diabetes drug Mounjaro share the same active ingredient, tirzepatide. Yet when CVS Caremark removed Zepbound last year, it left Mounjaro in place. The reasoning behind that split decision has never been publicly explained, a gap that invites skepticism about whether these formulary choices are driven by clinical logic or by the economics of rebate negotiations.
The FDA's recent moves to block compounding pharmacies from making cheaper versions of popular weight-loss drugs have only intensified the debate over access and affordability. Patients caught between high list prices and restrictive formularies have fewer escape valves than they might expect.
CVS Caremark's announcement comes with an important caveat that patients should not overlook. Being listed on the standard formulary does not guarantee that every employer-sponsored plan will actually cover the drug. Employers make the final call on which medications their plans include, and some may choose not to add Zepbound even after CVS Caremark opens the door.
That means some of the 25 to 30 million people on CVS Caremark's standard formulary could still find themselves without coverage come October. The $25 copay that Lilly touted applies only to "some patients with private insurance", language that leaves plenty of room for higher costs depending on plan design.
New players are trying to disrupt the status quo. Amazon recently entered the GLP-1 weight-loss market with aggressive pricing, a move that could pressure traditional pharmacy benefit managers to compete more transparently on cost.
Meanwhile, the Trump administration has pursued its own approach to lowering prescription costs. The expansion of TrumpRx to include more than 600 generic drugs reflects a push to give patients direct-to-consumer options that bypass the opaque middleman model entirely.
The Zepbound saga illustrates a structural problem that neither party has fully solved. Pharmacy benefit managers sit between drugmakers, insurers, and patients, extracting value at every turn. Their formulary decisions can redirect billions of dollars in drug spending, and they make those decisions largely outside public view.
When CVS Caremark removed Zepbound, patients bore the cost. They paid more out of pocket. They switched medications. They filed lawsuits. And now, roughly a year later, CVS Caremark is quietly putting the drug back, without explaining what changed or acknowledging that its original decision caused real harm.
Efforts to inject price transparency into the system, including Humana's recent deal with Mark Cuban's Cost Plus Drugs, show that alternatives exist when companies are willing to compete on price rather than on rebate leverage.
The class-action lawsuit remains active. The formulary change takes effect October 1. Between now and then, millions of patients wait, again, on a decision made by a corporate intermediary that has offered no public explanation for why it reversed itself.
When the people making the decisions never have to explain them, and the people living with the consequences never get a vote, the system is working exactly as designed. Just not for patients.